Research Paper Volume 15, Issue 10 pp 4411—4428

Brevilin A shows an anti-tumor role in prostate cancer via the lncRNA H19/miR-194/E2F3 signaling pathway


Figure 1. Brevilin A dampened prostate cancer cell proliferation. Brevilin A of different concentrations (0–80 μM) was adopted to treat prostate cancer cells (PC3, LNCap, DU145). (AC) CCK8 assay examined cell viability. (DF) Transwell checked cell migration and invasion. (G) TUNEL assay monitored apoptosis of PC3, LNCap, DU145 cells. (H) DU145 cells were taken to construct a nude mouse xenograft model of prostate cancer, and Brevilin A (10 mg/kg, 20 mg/kg) was administered for treatment. The tumors were excised 28 days later. (I, J) Tumor volume and tumor weight were calculated every 7 days. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001 (vs. control).